NEW YORK, March 30 (GenomeWeb News) - Ipsogen has obtained an exclusive worldwide license from three French institutions to a mutation in the JAK2 gene believed to enable researchers to better classify myeloproliferative disorders, the company said today.
It licensed the mutated tyrosine kinase from the Institut Gustave Roussy, the French National Health and Medical Research Institute, and Assistance Publique-Hôpitaux de Paris.
If used as a biomarker, the mutation can provide information about the nature of an elevated platelet or red blood cell count, which occurs frequently. Ipsogen said it is developing a "decentralized" CE marked test that will integrate the company's FusionQuant and ProfileQuant technologies.
Financial terms of the agreement were not disclosed.